Volume 142, Issue 4, Pages (April 2012)

Slides:

Advertisements

Similar presentations

Hepatitis web study Hepatitis web study Simeprevir in Genotype 1 (Viral Relapsers) PROMISE Trial Phase 3 Treatment Experienced Forns X, et al. Gastroenterology.

Advertisements

Gastroenterology Volume 142, Issue 4, April 2012, Pages 790–795 Tom W. Chu.

Ashutosh Gupta, Bashar M. Attar, Vikram Kotwal

Which patients with genotype 1 chronic hepatitis C can benefit from prolonged treatment with the ‘accordion’ regimen? Patrick Marcellin, E. Jenny Heathcote,

A Polymorphism in Interferon L3 Is an Independent Risk Factor for Development of Hepatocellular Carcinoma After Treatment of Hepatitis C Virus Infection

Chronic Hepatitis C Therapy: Changing the Rules of Duration

Volume 151, Issue 5, Pages (November 2016)

Les Lang Gastroenterology Volume 133, Issue 1, (July 2007)

Management of Patients Coinfected With HCV and HIV: A Close Look at the Role for Direct-Acting Antivirals Susanna Naggie, Mark S. Sulkowski Gastroenterology

Les Lang Gastroenterology Volume 133, Issue 1, (July 2007)

Covering the Cover Gastroenterology

New Hepatitis C Therapies: The Toolbox, Strategies, and Challenges

Effectiveness of Hepatitis B Treatment in Clinical Practice

Volume 132, Issue 3, Pages (March 2007)

Is HCV Infection a Neurologic Disorder?

Volume 146, Issue 3, Pages e1 (March 2014)

Outcomes Among Living Liver Donors

Lost in Inflammation: The Functional Conversion of Regulatory T Cells in Acute Hepatitis A Virus Infection Tobias Boettler, Robert Thimme Gastroenterology

Volume 143, Issue 3, Pages e5 (September 2012)

Improved Virologic Response in Chronic Hepatitis C Genotype 4 Treated With Nitazoxanide, Peginterferon, and Ribavirin Jean–François Rossignol, Asem Elfert,

Volume 59, Issue 4, Pages (October 2013)

Volume 146, Issue 2, Pages (February 2014)

Volume 151, Issue 4, Pages e1 (October 2016)

Michael Biermer, Thomas Berg Gastroenterology

Covering the Cover Gastroenterology

Volume 150, Issue 4, Pages (April 2016)

Volume 154, Issue 4, Pages (March 2018)

Volume 155, Issue 5, Pages e2 (November 2018)

Jean-Michel Pawlotsky Gastroenterology

Volume 136, Issue 2, Pages e3 (February 2009)

Volume 141, Issue 5, Pages (November 2011)

Combination of Vaniprevir With Peginterferon and Ribavirin Significantly Increases the Rate of SVR in Treatment-Experienced Patients With Chronic HCV.

Volume 152, Issue 1, Pages e4 (January 2017)

Early Virologic Responses and Hematologic Safety of Direct-Acting Antiviral Therapies in Veterans With Chronic Hepatitis C Pamela S. Belperio, Elizabeth.

Nghia H. Nguyen, Vincent Nguyen, Huy N. Trinh, Brian Lin, Mindie H

Volume 143, Issue 5, Pages e6 (November 2012)

Update on the Use of Vonoprazan: A Competitive Acid Blocker

The Combination of Simeprevir and Sofosbuvir Is More Effective Than That of Peginterferon, Ribavirin, and Sofosbuvir for Patients With Hepatitis C–Related.

Volume 135, Issue 5, Pages (November 2008)

New HCV therapies on the horizon

Ashutosh Gupta, Bashar M. Attar, Vikram Kotwal

Volume 142, Issue 6, Pages (May 2012)

Safety and Antiviral Activity of Albinterferon Alfa-2b in Prior Interferon Nonresponders With Chronic Hepatitis C David R. Nelson, Vinod Rustgi, Vijayan.

Volume 138, Issue 7, Pages (June 2010)

Rafael Esteban, Maria Buti Gastroenterology

Covering the Cover Gastroenterology

Chronic Hepatitis C Therapy: Changing the Rules of Duration

A Selection of the Best AGA Abstracts of DDW 2017

Volume 133, Issue 2, Pages (August 2007)

Interleukin-28b: A Key Piece of the Hepatitis C Virus Recovery Puzzle

Volume 145, Issue 4, Pages e3 (October 2013)

Ashwin N. Ananthakrishnan, David Lieberman Gastroenterology

Volume 132, Issue 1, Pages 5-6 (January 2007)

Volume 148, Issue 3, Pages (March 2015)

Genetic Factors and Hepatitis C Virus Infection

Volume 141, Issue 6, Pages (December 2011)

Statin Therapy Improves Sustained Virologic Response Among Diabetic Patients With Chronic Hepatitis C Gowtham A. Rao, Prashant K. Pandya Gastroenterology

Volume 143, Issue 3, Pages e5 (September 2012)

Secondary Prophylaxis of Hepatic Encephalopathy: An Open-Label Randomized Controlled Trial of Lactulose Versus Placebo Barjesh Chander Sharma, Praveen.

Christos Konstantakis, Maria Karamesini, Christos Triantos

Volume 130, Issue 7, Pages (June 2006)

Volume 156, Issue 3, Pages (February 2019)

Eradication Therapy for Helicobacter pylori

Volume 139, Issue 6, Pages e1 (December 2010)

Volume 139, Issue 5, Pages (November 2010)

Volume 147, Issue 6, Pages (December 2014)

Covering the Cover Gastroenterology

Detection of HCV RNA in Sustained Virologic Response to Direct-Acting Antiviral Agents: Occult or Science Fiction? Masaru Enomoto, Yoshiki Murakami,

The Results of Phase III Clinical Trials With Telaprevir and Boceprevir Presented at the Liver Meeting 2010: A New Standard of Care for Hepatitis C Virus.

Induction Pegylated Interferon Alfa-2b in Combination With Ribavirin in Patients With Genotypes 1 and 4 Chronic Hepatitis C: A Prospective, Randomized,

Presentation transcript:

Volume 142, Issue 4, Pages 790-795 (April 2012) Effect of IL28B Genotype on Early Viral Kinetics During Interferon-Free Treatment of Patients With Chronic Hepatitis C Tom W. Chu, Rohit Kulkarni, Edward J. Gane, Stuart K. Roberts, Catherine Stedman, Peter W. Angus, Brett Ritchie, Xiao-Yu Lu, David Ipe, Uri Lopatin, Soren Germer, Victor A. Iglesias, Robert Elston, Patrick F. Smith, Nancy S. Shulman Gastroenterology Volume 142, Issue 4, Pages 790-795 (April 2012) DOI: 10.1053/j.gastro.2011.12.057 Copyright © 2012 AGA Institute Terms and Conditions

Figure 1 Study design of the INFORM-1 trial. Patients with chronic HCV infection, including treatment naive, interferon treatment failure (partial responder and relapse), and interferon null responders, were randomized to either active study drugs or matching placebo by cohort. Patients received interferon-free combinations of mericitabine and danoprevir at increasing doses. The patients were allowed to initiate pegylated interferon/ribavirin treatment after completion of active study drug dosing. Gastroenterology 2012 142, 790-795DOI: (10.1053/j.gastro.2011.12.057) Copyright © 2012 AGA Institute Terms and Conditions

Figure 2 Mean change in serum HCV RNA level between study days 1 and 14 by rs12979860 genotype in all patients in cohorts C–G (n = 45) who received 13 days of dual oral combination therapy with mericitabine plus danoprevir. Gastroenterology 2012 142, 790-795DOI: (10.1053/j.gastro.2011.12.057) Copyright © 2012 AGA Institute Terms and Conditions

Figure 3 Mean change in serum HCV RNA level between study days 1 and 14 by rs12979860 genotype in all patients in the 2 highest dose cohorts (F and G; n = 15) in which patients received 13 days of dual oral combination therapy with mericitabine 1000 mg twice daily plus danoprevir 900 mg twice daily. Gastroenterology 2012 142, 790-795DOI: (10.1053/j.gastro.2011.12.057) Copyright © 2012 AGA Institute Terms and Conditions

Figure 4 Early viral kinetics during combination treatment (ie, day 1 to day 14) by IL28B genotype for all subjects in active arm from cohorts C to G who received 13 days of dual oral combination therapy with mericitabine plus danoprevir. Gastroenterology 2012 142, 790-795DOI: (10.1053/j.gastro.2011.12.057) Copyright © 2012 AGA Institute Terms and Conditions